Open AccessReduction of End‐stage Malignant Glioma by Injection with Autologous Cytotoxic T Lymphocytes
Author(s) -
Tsurushima Hideo,
Liu Shu Qin,
Tuboi Koji,
Matsumura Akira,
Yoshii Yoshihiko,
Nose Tadao,
Saijo Kaoru,
Ohno Tadao
Publication year - 1999
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1999.tb00781.x
Subject(s) - ctl* , anaplastic astrocytoma , glioma , cytotoxic t cell , medicine , immunotherapy , cd8 , pathology , peripheral blood mononuclear cell , ommaya reservoir , astrocytoma , brain tumor , cancer research , chemotherapy , antigen , immunology , in vitro , biology , immune system , biochemistry
Autologous cytotoxic T lymphocytes (CTL) against primary‐cultured malignant gliomas were generated from peripheral blood mononuclear cells in vitro in 4 patients. Activities of the CTL were highly specific to the corresponding autologous glioma and were inhibited, in one patient, with antibodies against CD3, CD8 and MHC‐class I molecules. When the CTL were injected 3 times into the primary‐tumor‐resected cavity via an Ommaya tube, reduction of the recurrent tumors with magnetic resonance imaging (MRI)‐measured volumes exceeding 45 cm 3 was observed in 3 patients. In a patient with glioblastoma multiforme (GBM), the tumor volume (estimated, 130 cm 3 ) was rapidly reduced to 1/3, although re‐recurrence of the tumor followed 40 days later. A slight but distinct rapid reduction of the tumor volume was observed in another GBM patient and in an anaplastic astrocytoma patient; essentially no change was observed in a further GBM patient. These results suggest that adoptive immunotherapy with autologous CTL will be clinically effective against end‐stage malignant gliomas.